{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/BMRN/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-18T16:00:10.518Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":2274,"canonical_name":"BIOMARIN PHARMACEUTICAL INC","cik":"0001048477","uei":null,"lei":null,"duns":null,"ticker":"BMRN"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":40},"count":40,"timeline":[{"ts":"2026-10-06","kind":"sec.filing","form_type":"8-K","title":"8-K — BIOMARIN PHARMACEUTICAL INC — 2026-10-06","url_slug":"/sec/cik-0001048477/8-k/0001048477-26-000019","accession_number":"0001048477-26-000019","importance":35},{"ts":"2026-10-01","kind":"sec.filing","form_type":"4","title":"4 — BIOMARIN PHARMACEUTICAL INC — 2026-10-01","url_slug":"/sec/cik-0001048477/4/0001628280-26-064272","accession_number":"0001628280-26-064272","importance":30},{"ts":"2026-09-30","kind":"sec.filing","form_type":"8-K","title":"8-K — BIOMARIN PHARMACEUTICAL INC — 2026-09-30","url_slug":"/sec/cik-0001048477/8-k/0001628280-26-063981","accession_number":"0001628280-26-063981","importance":35},{"ts":"2026-09-15","kind":"sec.filing","form_type":"8-K","title":"8-K — BIOMARIN PHARMACEUTICAL INC — 2026-09-15","url_slug":"/sec/cik-0001048477/8-k/0001628280-26-061973","accession_number":"0001628280-26-061973","importance":35},{"ts":"2026-09-14","kind":"sec.filing","form_type":"8-K","title":"8-K — BIOMARIN PHARMACEUTICAL INC — 2026-09-14","url_slug":"/sec/cik-0001048477/8-k/0001628280-26-061717","accession_number":"0001628280-26-061717","importance":35},{"ts":"2026-09-14","kind":"sec.filing","form_type":"3","title":"3 — BIOMARIN PHARMACEUTICAL INC — 2026-09-14","url_slug":"/sec/cik-0001048477/3/0001628280-26-061934","accession_number":"0001628280-26-061934","importance":30},{"ts":"2026-09-14","kind":"sec.filing","form_type":"4","title":"4 — BIOMARIN PHARMACEUTICAL INC — 2026-09-14","url_slug":"/sec/cik-0001048477/4/0001628280-26-061940","accession_number":"0001628280-26-061940","importance":30},{"ts":"2026-09-03","kind":"sec.filing","form_type":"4","title":"4 — BIOMARIN PHARMACEUTICAL INC — 2026-09-03","url_slug":"/sec/cik-0001048477/4/0001628280-26-060572","accession_number":"0001628280-26-060572","importance":30},{"ts":"2026-09-02","kind":"sec.filing","form_type":"144","title":"144 — BIOMARIN PHARMACEUTICAL INC — 2026-09-02","url_slug":"/sec/cik-0001048477/144/0001959173-26-006644","accession_number":"0001959173-26-006644","importance":30},{"ts":"2026-09-01","kind":"sec.filing","form_type":"8-K","title":"8-K — BIOMARIN PHARMACEUTICAL INC — 2026-09-01","url_slug":"/sec/cik-0001048477/8-k/0001193125-26-377696","accession_number":"0001193125-26-377696","importance":35},{"ts":"2026-08-31","kind":"sec.filing","form_type":"8-K","title":"8-K — BIOMARIN PHARMACEUTICAL INC — 2026-08-31","url_slug":"/sec/cik-0001048477/8-k/0001193125-26-375275","accession_number":"0001193125-26-375275","importance":35},{"ts":"2026-08-18","kind":"sec.filing","form_type":"8-K","title":"8-K — BIOMARIN PHARMACEUTICAL INC — 2026-08-18","url_slug":"/sec/cik-0001048477/8-k/0001193125-26-354780","accession_number":"0001193125-26-354780","importance":35},{"ts":"2026-08-06","kind":"sec.filing","form_type":"10-Q","title":"10-Q — BIOMARIN PHARMACEUTICAL INC — 2026-08-06","url_slug":"/sec/cik-0001048477/10-q/0001048477-26-000016","accession_number":"0001048477-26-000016","importance":45},{"ts":"2026-08-06","kind":"sec.filing","form_type":"8-K","title":"8-K — BIOMARIN PHARMACEUTICAL INC — 2026-08-06","url_slug":"/sec/cik-0001048477/8-k/0001048477-26-000015","accession_number":"0001048477-26-000015","importance":35},{"ts":"2026-08-06","kind":"sec.filing","form_type":"S-8","title":"S-8 — BIOMARIN PHARMACEUTICAL INC — 2026-08-06","url_slug":"/sec/cik-0001048477/s-8/0001193125-26-338468","accession_number":"0001193125-26-338468","importance":30},{"ts":"2026-07-13","kind":"sec.filing","form_type":"8-K/A","title":"8-K/A — BIOMARIN PHARMACEUTICAL INC — 2026-07-13","url_slug":"/sec/cik-0001048477/8-k-a/0001048477-26-000011","accession_number":"0001048477-26-000011","importance":30},{"ts":"2026-06-04","kind":"sec.filing","form_type":"8-K","title":"8-K — BIOMARIN PHARMACEUTICAL INC — 2026-06-04","url_slug":"/sec/cik-0001048477/8-k/0001628280-26-040812","accession_number":"0001628280-26-040812","importance":35},{"ts":"2026-06-04","kind":"sec.filing","form_type":"4","title":"4 — BIOMARIN PHARMACEUTICAL INC — 2026-06-04","url_slug":"/sec/cik-0001048477/4/0001628280-26-040903","accession_number":"0001628280-26-040903","importance":30},{"ts":"2026-06-04","kind":"sec.filing","form_type":"4","title":"4 — BIOMARIN PHARMACEUTICAL INC — 2026-06-04","url_slug":"/sec/cik-0001048477/4/0001628280-26-040907","accession_number":"0001628280-26-040907","importance":30},{"ts":"2026-06-04","kind":"sec.filing","form_type":"4","title":"4 — BIOMARIN PHARMACEUTICAL INC — 2026-06-04","url_slug":"/sec/cik-0001048477/4/0001628280-26-040909","accession_number":"0001628280-26-040909","importance":30},{"ts":"2026-06-04","kind":"sec.filing","form_type":"4","title":"4 — BIOMARIN PHARMACEUTICAL INC — 2026-06-04","url_slug":"/sec/cik-0001048477/4/0001628280-26-040911","accession_number":"0001628280-26-040911","importance":30},{"ts":"2026-06-04","kind":"sec.filing","form_type":"4","title":"4 — BIOMARIN PHARMACEUTICAL INC — 2026-06-04","url_slug":"/sec/cik-0001048477/4/0001628280-26-040914","accession_number":"0001628280-26-040914","importance":30},{"ts":"2026-06-04","kind":"sec.filing","form_type":"4","title":"4 — BIOMARIN PHARMACEUTICAL INC — 2026-06-04","url_slug":"/sec/cik-0001048477/4/0001628280-26-040916","accession_number":"0001628280-26-040916","importance":30},{"ts":"2026-06-04","kind":"sec.filing","form_type":"4","title":"4 — BIOMARIN PHARMACEUTICAL INC — 2026-06-04","url_slug":"/sec/cik-0001048477/4/0001628280-26-040918","accession_number":"0001628280-26-040918","importance":30},{"ts":"2026-06-04","kind":"sec.filing","form_type":"4","title":"4 — BIOMARIN PHARMACEUTICAL INC — 2026-06-04","url_slug":"/sec/cik-0001048477/4/0001628280-26-040920","accession_number":"0001628280-26-040920","importance":30},{"ts":"2026-06-04","kind":"sec.filing","form_type":"4","title":"4 — BIOMARIN PHARMACEUTICAL INC — 2026-06-04","url_slug":"/sec/cik-0001048477/4/0001628280-26-040922","accession_number":"0001628280-26-040922","importance":30},{"ts":"2026-06-02","kind":"sec.insider.a","reporter":"ANDERSON ELIZABETH M","title":null,"shares":7490,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-02","kind":"sec.insider.a","reporter":"Bodem Barbara W.","title":null,"shares":7490,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-02","kind":"sec.insider.a","reporter":"CLARK IAN T","title":null,"shares":7490,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-02","kind":"sec.insider.a","reporter":"Dere Willard H","title":null,"shares":7490,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-02","kind":"sec.insider.a","reporter":"Enyedy Mark J","title":null,"shares":7490,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-02","kind":"sec.insider.a","reporter":"Ho Maykin","title":null,"shares":7490,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-02","kind":"sec.insider.a","reporter":"HOMBACH ROBERT J.","title":null,"shares":7490,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-02","kind":"sec.insider.a","reporter":"Walbert Timothy P","title":null,"shares":7490,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-02","kind":"sec.insider.a","reporter":"Countouriotis Athena","title":null,"shares":7490,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-21","kind":"sec.filing","form_type":"4","title":"4 — BIOMARIN PHARMACEUTICAL INC — 2026-05-21","url_slug":"/sec/cik-0001048477/4/0001628280-26-037455","accession_number":"0001628280-26-037455","importance":30},{"ts":"2026-05-20","kind":"sec.insider.f","reporter":"Hubbard Cristin","title":"EVP, Chief Commercial Officer","shares":2318,"price_per_share":50.2,"usd_value":116364,"security_title":"Common Stock","importance":15.1163636},{"ts":"2026-05-11","kind":"sec.filing","form_type":"4","title":"4 — BIOMARIN PHARMACEUTICAL INC — 2026-05-11","url_slug":"/sec/cik-0001048477/4/0001628280-26-033639","accession_number":"0001628280-26-033639","importance":30},{"ts":"2026-05-07","kind":"sec.insider.s","reporter":"Friberg Gregory R","title":"EVP, Chief R&D Officer","shares":3281,"price_per_share":53.85,"usd_value":176682,"security_title":"Common Stock","importance":35.17668185},{"ts":"2026-04-27","kind":"sec.filing","form_type":"8-K","title":"8-K — BIOMARIN PHARMACEUTICAL INC — 2026-04-27","url_slug":"/sec/cik-0001048477/8-k/0001193125-26-179243","accession_number":"0001193125-26-179243","importance":35}]}